 |
NEWS RELEASE |
| CONTACT: | |
| CONMED Corporation | |
| Robert Shallish | |
| Chief Financial Officer | |
| 315-624-3206 | |
| FTI Consulting | |
| Investors: Brian Ritchie | |
| 212-850-5600 |
FOR RELEASE: 7:00 AM (Eastern) April 26, 2012
CONMED Corporation Announces First Quarter 2012 Financial Results
- Sales Increase Approximately 6%
- GAAP EPS Increases Approximately 13%
- Adjusted EPS Increases Over 16%
- Conference Call to be Held at 10:00 a.m. ET Today -
Utica, New York, April 26, 2012 ----- CONMED Corporation (Nasdaq: CNMD) today announced financial results for the first quarter ended March 31, 2012.
“CONMED is off to a solid start in 2012 with double digit earnings growth and a sales increase of approximately six percent. Both sales and adjusted earnings were within the ranges of our expectations for the quarter,” commented Mr. Joseph J. Corasanti, President and CEO. “The Company’s single-use product revenues continue to perform well, with overall growth of nine percent in the first quarter. Moreover, our new relationship with the Musculoskeletal Transplant Foundation has already proven to be a highly-beneficial addition to our Sports Medicine/Arthroscopy offering.”
As discussed below under “Use of Non-GAAP Financial Measures,” the Company presents various non-GAAP adjusted financial measures in this release. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with generally accepted accounting principles (“GAAP”). Please refer to the attached reconciliation between GAAP and adjusted financial measures.
First Quarter 2012 Financial Highlights:
| · | Sales grew to $194.3 million, an increase of 5.9% (organic growth of 1.8%). |
| · | Single-use products comprised 79.4% of total revenues and grew 9.0%, while sales of capital products declined 4.5%. |
| · | Diluted earnings per share (GAAP) grew 12.9% to $0.35 |
| · | Adjusted diluted earnings per share grew 16.2% to $0.43. |
| · | Adjusted operating margin expanded 30 basis points to 10.5%. |
| CONMED News Release Continued | Page 2 of 10 | April 26, 2012 |
| · | GAAP operating margin was 8.8%. |
| · | The Board of Directors initiated a cash dividend policy and declared the first quarterly dividend of $0.15 per share which was paid on April 5, 2012. |
International sales in the first quarter of 2012 were $98.2 million, representing 50.5% of total sales. Foreign currency exchange rates were approximately the same in the first quarter of 2012 compared to rates in the first quarter of 2011.
Cash provided by operating activities declined from the first quarter of 2011 due to an increase in accounts receivable from higher sales, a contribution of $6.5 million to the Company’s frozen pension plan and payment of incentive compensation. Management expects quarterly cash flow to improve in the remaining quarters of 2012 since the pension and incentive compensation payments only affect the first quarter of 2012.
Outlook
“We expect to sustain the momentum from the first quarter and continue to deliver double digit earnings growth for the remainder of 2012,” continued Mr. Corasanti. “However, while we do think the capital equipment business is beginning to stabilize, in light of the relatively soft sales from this product category in the first quarter, we are tightening our adjusted earnings per share guidance for the full year of 2012 by reducing the top end of our previous estimate. We now expect that adjusted earnings per share for 2012 will approximate $1.75 - $1.85, as opposed to our previously issued guidance of $1.75 - $1.88. This range would result in an increase in adjusted EPS of between 17 and 23 percent over 2011. The sales forecast for 2012 has been revised accordingly to $775 - $785 million from $780 - $790 million.”
“For the second quarter of 2012, we anticipate sales will approximate $190 - $195 million and adjusted earnings per share are forecasted to be $0.42 - $0.47,” noted Mr. Corasanti.
The sales and earnings forecasts have been developed using April 2012 currency exchange rates and take into account the currency hedges entered into by the Company. CONMED estimates that 80% of the currency exposure is hedged for 2012 at the following average annual exchange rates: Euro - $1.41, CAD - $1.00, GPB - $1.60 and AUD - $1.00.
The adjusted estimates for the second quarter and full year 2012 exclude unusual matters, such as the manufacturing restructuring costs expected to be incurred in 2012 due to the relocation of manufacturing activities from the Santa Barbara, California site to the Company’s facilities in Chihuahua, Mexico and Largo, Florida. Marketing and R&D activities will remain in Santa Barbara, as previously disclosed.
Association with The Musculoskeletal Transplant Foundation
On January 3, 2012, CONMED became the exclusive world-wide marketing representative of MTF’s sports medicine allograft tissues. In accordance with MTF’s commitment to the stewardship of the donated gift, the organization maintains full responsibility for all activities related to donor suitability, quality acceptance, processing, storage, and distribution of the tissue, as well as reimbursement of service fees related to the sports medicine allografts. CONMED’s team of surgical representatives serves as the educational resource to surgeons and facilities concerning the suitability of MTF allografts for ligament reconstruction, cartilage repair and meniscal transplantation, as well as for biologic solutions, including scaffolds and fixation devices. MTF will share 50% of the service revenue with CONMED for these educational activities.
Upon signing of the agreement, CONMED paid $63 million to MTF. The agreement calls for additional consideration to be paid to MTF of $84 million over the next four years contingent upon MTF providing an adequate supply of tissue. We have recorded the full amount of the consideration as a long term asset and amortize this amount ratably over the 25 year life of the agreement. Remaining contingent payments to MTF have been recorded as other liabilities. In the three months ended March, 2012, we recorded gross revenues from MTF of $9.0 million which were reduced by amortization of $1.5 million resulting in net revenues of $7.5 million.
| CONMED News Release Continued | Page 3 of 10 | April 26, 2012 |
Unusual charges
During the first quarter of 2012, the Company continued the on-going consolidation of certain administrative functions and the transfer of additional product lines to its Mexican manufacturing facility. Also incurred were integration costs relative to the purchase of a distributor in northern Europe and litigation costs associated with an arbitration matter. Expenses associated with these activities, including severance and relocation costs, amounted to $2.2 million, net of tax, in the first quarter of 2012. These charges are included in the GAAP earnings per share set forth above and are excluded from the adjusted results. For the remainder of 2012, the Company presently anticipates incurring additional pre-tax restructuring costs of $2.5 - $3.5 million on projects currently in process.
Convertible note amortization of debt discount
Through November 2011, the Company recorded non-cash interest expense related to its convertible notes to bring the effective interest rate to a level approximating that of a non-convertible note of similar size and tenor. Substantially all of the notes were redeemed in November 2011. Accordingly, the fourth quarter of 2011 was the last quarter of such additional interest expense. In the first quarter of 2011, CONMED recorded additional non-cash pre-tax interest charges of $1.1 million. These charges were included in the GAAP earnings per share for 2011 and excluded from the 2011 non-GAAP amounts.
Use of non-GAAP financial measures
Management has disclosed adjusted financial measurements in this press announcement that present financial information that is not in accordance with generally accepted accounting principles. These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company’s on-going financial performance from quarter-to-quarter and year-to-year on a regular basis, and for benchmarking against other medical technology companies. Adjusted net income and adjusted earnings per share measure the income of the Company excluding unusual credits or charges that are considered by management to be outside of the normal on-going operations of the Company. Management uses and presents adjusted net income and adjusted earnings per share because management believes that in order to properly understand the Company’s short and long-term financial trends, the impact of unusual items should be eliminated from on-going operating activities. These adjustments for unusual items are derived from facts and circumstances that vary in frequency and impact on the Company’s results of operations. Management uses adjusted net income and adjusted earnings per share to forecast and evaluate the operational performance of the Company as well as to compare results of current periods to prior periods on a consistent basis. Adjusted financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.
Conference call
The Company will webcast its first quarter 2012 conference call live over the Internet at 10:00 a.m. Eastern Time on Thursday, April 26, 2012. This webcast can be accessed from CONMED’s web site at www.conmed.com. Replays of the call will be made available through May 4, 2012.
CONMED profile
CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company’s products serve the clinical areas of arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. They are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company’s 3,400 employees distribute its products worldwide from several manufacturing locations.
| CONMED News Release Continued | Page 4 of 10 | April 26, 2012 |
Forward Looking Information
This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw material, transportation of litigation; (viii) the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues; and/or (ix) the Company’s ability to devise and execute strategies to respond to market conditions.
| CONMED News Release Continued | Page 5 of 10 | April 26, 2012 |
CONMED CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
Three Months Ended March 31, 2011 and 2012
(In thousands except per share amounts)
(unaudited)
| 2011 | 2012 | |||||||
| Net sales | $ | 183,450 | $ | 194,316 | ||||
| Cost of sales | 86,980 | 91,931 | ||||||
| Cost of sales, other - Note A | 754 | 1,474 | ||||||
| Gross profit | 95,716 | 100,911 | ||||||
| Selling and administrative | 70,078 | 74,806 | ||||||
| Research and development | 7,681 | 7,095 | ||||||
| Other expense – Note B | 694 | 1,988 | ||||||
| 78,453 | 83,889 | |||||||
| Income from operations | 17,263 | 17,022 | ||||||
| Amortization of debt discount | 1,094 | — | ||||||
| Interest expense | 1,805 | 1,437 | ||||||
| Income before income taxes | 14,364 | 15,585 | ||||||
| Provision for income taxes | 5,369 | 5,617 | ||||||
| Net income | $ | 8,995 | $ | 9,968 | ||||
| Per share data: | ||||||||
| Net income | ||||||||
| Basic | $ | .32 | $ | .36 | ||||
| Diluted | .31 | .35 | ||||||
| Weighted average common shares | ||||||||
| Basic | 28,261 | 28,029 | ||||||
| Diluted | 28,701 | 28,484 | ||||||
Note A –Included in cost of sales, other in the three months ended March 31, 2011 and 2012, are $0.8 million and $1.5 million, respectively, related to the moving of additional product lines to the manufacturing facility in Chihuahua, Mexico.
Note B – Included in other expense in the three months ended March 31, 2011 and 2012, are $0.7 million and $0.3 million, respectively, related to administrative consolidation expense. Also included in other expense in the three months ended March 31, 2012 is $0.7 million in cost associated with the acquisition of our former distributor in the Nordic region of Europe and $1.0 million in costs associated with legal arbitration.
| CONMED News Release Continued | Page 6 of 10 | April 26, 2012 |
CONMED CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(in thousands)
(unaudited)
ASSETS
| December 31, | March 31, | |||||||
| 2011 | 2012 | |||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 26,048 | $ | 19,454 | ||||
| Accounts receivable, net | 135,641 | 142,351 | ||||||
| Inventories | 168,438 | 163,390 | ||||||
| Deferred income taxes | 10,283 | 10,951 | ||||||
| Other current assets | 16,314 | 15,132 | ||||||
| Total current assets | 356,724 | 351,278 | ||||||
| Property, plant and equipment, net | 139,187 | 141,032 | ||||||
| Deferred income taxes | 2,389 | 2,422 | ||||||
| Goodwill | 234,815 | 234,794 | ||||||
| Other intangible assets, net | 195,531 | 193,643 | ||||||
| Other assets | 6,948 | 153,391 | ||||||
| Total assets | $ | 935,594 | $ | 1,076,560 | ||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Current portion of long-term debt | $ | 54,557 | $ | 54,219 | ||||
| Other current liabilities | 76,627 | 111,626 | ||||||
| Total current liabilities | 131,184 | 165,845 | ||||||
| Long-term debt | 88,952 | 138,952 | ||||||
| Deferred income taxes | 92,785 | 95,791 | ||||||
| Other long-term liabilities | 49,602 | 89,247 | ||||||
| Total liabilities | 362,523 | 489,835 | ||||||
| Shareholders' equity: | ||||||||
| Capital accounts | 244,980 | 251,811 | ||||||
| Retained earnings | 354,439 | 360,185 | ||||||
| Accumulated other comprehensive loss | (26,348 | ) | (25,271 | ) | ||||
| Total equity | 573,071 | 586,725 | ||||||
| Total liabilities and shareholders' equity | $ | 935,594 | $ | 1,076,560 | ||||
| CONMED News Release Continued | Page 7 of 10 | April 26, 2012 |
CONMED CORPORATION
CONSOLIDATED CONDENSED STATEMENT OF CASH FLOWS
(in thousands)
(unaudited)
| Three months ended | ||||||||
| March 31, | ||||||||
| 2011 | 2012 | |||||||
| Cash flows from operating activities: | ||||||||
| Net income | $ | 8,995 | $ | 9,968 | ||||
| Adjustments to reconcile net income | ||||||||
| to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 10,340 | 11,812 | ||||||
| Stock-based compensation | 1,026 | 1,183 | ||||||
| Deferred income taxes | 4,625 | 2,735 | ||||||
| Increase (decrease) in cash flows from changes in assets and liabilities: | ||||||||
| Accounts receivable | 90 | (5,618 | ) | |||||
| Inventories | 420 | 2,764 | ||||||
| Accounts payable | 1,782 | 2,601 | ||||||
| Income taxes payable | 333 | (1,232 | ) | |||||
| Accrued compensation and benefits | (7,442 | ) | (10,446 | ) | ||||
| Other assets | (1,917 | ) | (1,106 | ) | ||||
| Other liabilities | 2,448 | (5,032 | ) | |||||
| Net cash provided by operating activities | 20,700 | 7,629 | ||||||
| Cash flow from investing activities: | ||||||||
| Purchases of property, plant and equipment | (4,143 | ) | (6,424 | ) | ||||
| Payments related to business acquisitions and distribution agreement | (72 | ) | (64,116 | ) | ||||
| Net cash used in investing activities | (4,215 | ) | (70,540 | ) | ||||
| Cash flow from financing activities: | ||||||||
| Payments on debt | (13,337 | ) | (338 | ) | ||||
| Proceeds from debt borrowings | — | 50,000 | ||||||
| Net proceeds from common stock issued under employee plans | 1,287 | 5,345 | ||||||
| Other, net | 337 | 809 | ||||||
| Net cash provided by (used in) financing activities | (11,713 | ) | 55,816 | |||||
| Effect of exchange rate change | ||||||||
| on cash and cash equivalents | 750 | 501 | ||||||
| Net increase (decrease) in cash and cash equivalents | 5,522 | (6,594 | ) | |||||
| Cash and cash equivalents at beginning of period | 12,417 | 26,048 | ||||||
| Cash and cash equivalents at end of period | $ | 17,939 | $ | 19,454 | ||||
| CONMED News Release Continued | Page 8 of 10 | April 26, 2012 |
CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO NON-GAAP NET INCOME
BEFORE UNUSUAL ITEMS AND AMORTIZATION OF DEBT DISCOUNT
Three Months Ended March 31, 2011 and 2012
(In thousands except per share amounts)
(unaudited)
| 2011 | 2012 | |||||||
| Reported net income | $ | 8,995 | $ | 9,968 | ||||
| Facility consolidation costs included in cost of sales | 754 | 1,474 | ||||||
| Administrative consolidation costs included in other expense | 694 | 273 | ||||||
| Costs associated with purchase of Nordic region distributor | — | 704 | ||||||
| Legal arbitration costs included in other expense | — | 1,011 | ||||||
| Total other expense | 694 | 1,988 | ||||||
| Amortization of debt discount | 1,094 | — | ||||||
| Unusual expense before income taxes | 2,542 | 3,462 | ||||||
| Provision (benefit) for income taxes on unusual expenses | (926 | ) | (1,246 | ) | ||||
| Net income before unusual items | $ | 10,611 | $ | 12,184 | ||||
| Per share data: | ||||||||
| Reported net income | ||||||||
| Basic | $ | 0.32 | $ | 0.36 | ||||
| Diluted | 0.31 | 0.35 | ||||||
| Net income before unusual items | ||||||||
| Basic | $ | 0.38 | $ | 0.43 | ||||
| Diluted | 0.37 | 0.43 | ||||||
Management has provided the above reconciliation of net income before unusual items and amortization of debt discount as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section “Use of Non-GAAP Financial Measures” above. We have included the amortization of debt discount in our analysis in order to facilitate comparison with the non-GAAP earnings guidance provided in the “Outlook” section of this and previous releases which exclude such expense.
| CONMED News Release Continued | Page 9 of 10 | April 26, 2012 |
CONMED CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
Three Months Ended March 31, 2011 and 2012
(In thousands)
(unaudited)
| 2011 | 2012 | |||||||
| Reported income from operations | $ | 17,263 | $ | 17,022 | ||||
| Facility consolidation costs included in cost of sales | 754 | 1,474 | ||||||
| Administrative consolidation costs included in other expense | 694 | 273 | ||||||
| Costs associated with purchase of Nordic region distributor | — | 704 | ||||||
| Legal arbitration costs included in other expense | — | 1,011 | ||||||
| Adjusted income from operations | $ | 18,711 | $ | 20,484 | ||||
| Operating Margin | ||||||||
| Reported (GAAP) | 9.4 | % | 8.8 | % | ||||
| Adjusted (Non-GAAP) | 10.2 | % | 10.5 | % | ||||
Management has provided the above reconciliation as an additional measure that investors can use to compare financial results between reporting periods. Management believes this reconciliation provides a useful presentation of financial measures as discussed in the section “Use of Non-GAAP Financial Measures” above.
| CONMED News Release Continued | Page 10 of 10 | April 26, 2012 |
CONMED CORPORATION
First Quarter Sales Summary
| Three Months Ended March 31, | ||||||||||||||||
| Constant | ||||||||||||||||
| Currency | ||||||||||||||||
| 2011 | 2012 | Growth | Growth | |||||||||||||
| (in millions) | ||||||||||||||||
| Arthroscopy | ||||||||||||||||
| Single-use | $ | 58.1 | $ | 69.2 | 19.1 | % | 18.3 | % | ||||||||
| Capital | 17.3 | 17.0 | -1.7 | % | -1.7 | % | ||||||||||
| 75.4 | 86.2 | 14.3 | % | 13.7 | % | |||||||||||
| Powered Surgical Instruments | ||||||||||||||||
| Single-use | 20.4 | 21.5 | 5.4 | % | 4.9 | % | ||||||||||
| Capital | 17.7 | 17.1 | -3.4 | % | -3.9 | % | ||||||||||
| 38.1 | 38.6 | 1.3 | % | 0.8 | % | |||||||||||
| Electrosurgery | ||||||||||||||||
| Single-use | 16.7 | 16.6 | -0.6 | % | -1.2 | % | ||||||||||
| Capital | 6.9 | 5.9 | -14.5 | % | -14.5 | % | ||||||||||
| 23.6 | 22.5 | -4.7 | % | -5.1 | % | |||||||||||
| Endoscopic Technologies | ||||||||||||||||
| Single-use | 11.9 | 12.8 | 7.6 | % | 7.6 | % | ||||||||||
| Endosurgery | ||||||||||||||||
| Single-use and reposable | 17.9 | 18.2 | 1.7 | % | 1.1 | % | ||||||||||
| Patient Care | ||||||||||||||||
| Single-use | 16.6 | 16.0 | -3.6 | % | -3.6 | % | ||||||||||
| Total | ||||||||||||||||
| Single-use and reposable | 141.6 | 154.3 | 9.0 | % | 8.4 | % | ||||||||||
| Capital | 41.9 | 40.0 | -4.5 | % | -4.8 | % | ||||||||||
| $ | 183.5 | $ | 194.3 | 5.9 | % | 5.4 | % | |||||||||